This proposal involves a series of coordinated, translational studies designed to establish the mechanisms by which important antipsychotic drugs might bring about cardiac arrhythmias and sudden death. While a great deal of research over the past thirty years has resulted in the recent appearance of antipsychotic drugs that have reduced extra-pyramidal side-effects, a number of these novel agents have recently been shown to possess the ability to prolong the electrocardiac QT interval, and cause potentially lethal torsades-de-pointes arrhythmias that are reminiscent of older agents. Using antipsychotic drugs chosen for their wide clinical use, and potential cardiotoxicity the investigator propose to study potential pharmacodynamic and pharmacokinetic mechanisms that might expose vulnerable patients to the risk of these arrhythmias. The present study will have the following specific aims: 1) To test in vitro whether antipsychotic their metabolites or combinations of drug and metabolite modulate cardiac electrophysiology in isolated perfused heart using the characteristics of the action potential (AP), QT interval and early after depolarization (EAD) occurrence. To investigate whether any electrophysiologic changes noted are the result of specific cardiac Na, Ca, or K, channel activity in isolated ventricular cardiomyocytes and Purkinje cells, using currient patch clamp techniques. Since the investigators have preliminary data that indicate that haloperidol can slow cardiac repolarization in vitro, the focus of our studies in the first year will be on this widely-used drug and its metabolites. In subsequent years, the investigators will evaluate thioridazine, fluphenazine and loxapine. 2) To probe the cytochrome P450 isoforms responsible for metabolism of antipsychotic drugs or metabolites that the investigators find to be cardiotoxic. This information will allow assessment of pharmacogenetic and pharmacokinetic influences that might increase the concentration of these agents, and the risk of arrhythmia. The investigators will document the cytochrome P450 isoforms responsible for the metabolism of specific drugs using isolated human hepatic, intestinal and cardiac microsomal preparations, isoform-specific inhibitors and antibodies, and recombinant cytochrome P450 isoforms. 3) To determine if antipsychotic agents that are found to be potentially cardiotoxic in vitro have clinical electrocardiac effects at the doses routinely used in healthy volunteers. The investigator will document the relationship between the serum concentrations of these drugs and their electrocardiac pharmacodynamics. The results of these studies should allow physicians and researchers to more confidently predict patients at risk for lethal torsades-de-pointes arrhythmias while taking neuroleptic drugs, and to gain mechanistic insights that will allow the design of safer drugs in the future.

Agency
National Institute of Health (NIH)
Institute
National Institute of General Medical Sciences (NIGMS)
Type
Research Project (R01)
Project #
5R01GM056898-02
Application #
6019397
Study Section
Special Emphasis Panel (ZRG4-ALTX-4 (01))
Project Start
1998-08-01
Project End
2002-07-31
Budget Start
1999-08-01
Budget End
2000-07-31
Support Year
2
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Georgetown University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
049515844
City
Washington
State
DC
Country
United States
Zip Code
20057
Jin, Yan; Hayes, Daniel F; Li, Lang et al. (2008) Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy. J Clin Oncol 26:5849-54
Li, Lang; Yu, Menggang; Jason, Robarge D et al. (2008) A mixture model approach in gene-gene and gene-environmental interactions for binary phenotypes. J Biopharm Stat 18:1150-77
Shin, Jae-Gook; Kang, Won-Ku; Shon, Ji-Hong et al. (2007) Possible interethnic differences in quinidine-induced QT prolongation between healthy Caucasian and Korean subjects. Br J Clin Pharmacol 63:206-15
Li, Lang; Yu, Menggang; Chin, Raymond et al. (2007) Drug-drug interaction prediction: a Bayesian meta-analysis approach. Stat Med 26:3700-21
Li, Lang; Hui, Siu; Pennello, Gene et al. (2007) Estimating a positive false discovery rate for variable selection in pharmacogenetic studies. J Biopharm Stat 17:883-902
Jin, Yan; Desta, Zeruesenay; Stearns, Vered et al. (2005) CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 97:30-9
Vitseva, Olga; Flockhart, David A; Jin, Yan et al. (2005) The effects of tamoxifen and its metabolites on platelet function and release of reactive oxygen intermediates. J Pharmacol Exp Ther 312:1144-50
Ward, Bryan A; Morocho, Alan; Kandil, Abdullah et al. (2004) Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro. Br J Clin Pharmacol 58:277-87
Stearns, V; Davidson, N E; Flockhart, D A (2004) Pharmacogenetics in the treatment of breast cancer. Pharmacogenomics J 4:143-53
Li, Lang; Desai, Mehul; Desta, Zeruesenay et al. (2004) QT analysis: a complex answer to a 'simple' problem. Stat Med 23:2625-43

Showing the most recent 10 out of 29 publications